Table 1.
The clinical application of m6A and PCD
| M6A associated molecules | Types of programmed cell death pathways | Molecular mechanisms | The corresponding cancers | Clinical application | Ref. |
|---|---|---|---|---|---|
| FTO | Apoptosis | Increased MZF1 expression | LUSC | Prognosis and therapy | [123] |
| METTL3 and IGFBP2 | Apoptosis | Promoted the stability of SEC62 mRNA | Gastric cancer | Prevention and management | [124] |
| METTL3 and YTHDF2 | Apoptosis | Mediated LHPP and NKX3–1 mRNA | Prostate cancer | Diagnosis and therapy | [125] |
| HNRNPC | Apoptosis | Downregulated miR-21 and AKT phosphorylation | Ovarian cancer | Prognosis | [126] |
| METTL3 | Autophagy | Stimulated autophagy of ARHGAP5-AS1 or destabilizing ARHGAP5 | Gastric cancer | Anti- chemoresistance and prognosis | [127] |
| METTL3 | Apoptosis | Impinged on critical cellular processes | Cervical cancer | Radio/ chemo-resistance | [128, 129] |
| METTL14 | Apoptosis | Targeted CXCR4 and CYP1B1 | Breast cancer | Diagnosis, therapy and prognosis | [94] |
| WTAP | Apoptosis | Affected PI3K/AKT signaling | AML | Prognosis | [130] |
| WTAP | Apoptosis | Regulated DUSP6 | NKTCL | Drug resistance | [131] |
| YTHDF2 | Apoptosis | Reduced the half-life of Tnfrsf2 | AML | Therapy | [132] |
| ALKBH5 | Apoptosis | Reduced m6A-methylated pre-miR-181b-1 and YAP | Osteosarcoma | Therapy | [133] |
|
ALKBH5 And YTHDF2 |
Apoptosis | Pancreatic cancer | Diagnosis and therapy | [134] | |
| FTO | Autophagy | Augmented m6A demethylation of ATG5 and ATG7 | Ovarian cancer | Diagnosis and therapy | [135] |
| FTO | Apoptosis | Caused inhibition of MYC/CEBPA signaling | Glioma | Anti-cancer activity | [136] |
| FTO | Apoptosis | Reduced hypomethylation and Bcl-2 transcripts | AML | Drug resistance | [137] |
| M6A | Apoptosis | Regulated the Daple/β-catenin/ABCC9 signaling pathway | NPC | Drug resistance | [138] |
| RBM15 | Apoptosis | Upregulated TMBIM6 m6A modification | LSCC | Therapy and Prognosis | [139] |
| FTO | Autophagy | Reduced m6A methylation of the critical protumorigenic melanoma cell-intrinsic genes containing PD-1(PDCD-1), CXCR4 and SOX10 and maintaining their mRNA stability | Melanoma | Immune therapy resistance | [103] |
| M6A writers | Apoptosis | Correlated with drugs which targeted oncogenic related pathways, such as MAPK, EGFR, and mTOR signaling pathways | Colorectal cancer | Immune therapy resistance | [140] |
LUSC lung squamous cell carcinoma, NKTCL Natural killer/T-cell lymphoma, DUSP6 dual-specificity phosphatases 6, YAP Yes-associated protein 1